MEDI4736
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Conditions
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Trial Timeline
Oct 23, 2014 → Jul 6, 2020
NCT ID
NCT02207530About MEDI4736
MEDI4736 is a phase 2 stage product being developed by AstraZeneca for Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck. The current trial status is completed. This product is registered under clinical trial identifier NCT02207530. Target conditions include Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02669914 | Phase 2 | Terminated |
| NCT02227667 | Phase 2 | Completed |
| NCT02207530 | Phase 2 | Completed |
| NCT02125461 | Phase 3 | Completed |
| NCT02087423 | Phase 2 | Completed |
Competing Products
20 competing products in Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck